Monoaminergic mechanisms and experimental cataplexy

Annals of Neurology
A S FoutzW C Dement

Abstract

The effects of pharmacological alteration of the monoamine systems were investigated in a canine model of narcolepsy. Cataplexy was quantified in eight severely affected dogs by means of the food-elicited cataplexy test. The specific norepinephrine (NE) uptake blocker nisoxetine, and (to a much lesser extent) the specific serotonin (5-HT) uptake blocker fluoxetine, significantly suppressed cataplexy, as did the tricyclic antidepressants protriptyline, amitriptyline, and chlorimipramine. Thus, experimental cataplexy is suppressed more by inhibition of the uptake of NE than of 5-HT. Methylphenidate, the alpha-adrenoreceptor blocker clonidine, and the dopamine receptor blocker pimozide also suppressed cataplexy in dogs. The beta-adrenergic blocker propranolol, the fatty acid gamma-hydroxybutyrate, and the monoamine oxidase inhibitors clorgyline and pargyline had little or no effect. With one exception (pimozide), all the drugs that suppressed cataplexy are known to be potent suppressors of REM sleep. The suppression of cataplexy induced by nisoxetine or protriptyline was reversed by the anticholinesterase physostigmine, further supporting a postulated aminergic-cholinergic interaction in the mechanisms for cataplexy.

References

Apr 1, 1978·Electroencephalography and Clinical Neurophysiology·G StockK H Schlör
Oct 1, 1979·Archives of Neurology·A KalesT L Tan
Dec 1, 1979·Experimental Neurology·J B DelashawW C Dement
Apr 1, 1978·Clinical Pharmacology and Therapeutics·L LembergerD Wong
Aug 1, 1976·Pharmacology, Biochemistry, and Behavior·E Hartmann, G Zwilling
Dec 1, 1976·Pharmacology, Biochemistry, and Behavior·D A BabcockM M Mitler
Jan 1, 1971·Psychopharmacologia·D L DunleavyI Oswald
Jul 7, 1980·Brain Research·A Leppävuori, P T Putkonen

❮ Previous
Next ❯

Citations

Nov 1, 1993·Progress in Neurobiology·M S Aldrich
May 1, 1997·Progress in Neurobiology·S Nishino, E Mignot
Mar 1, 1996·Seminars in Pediatric Neurology·S Kotagal
Oct 29, 2003·Clinical Neurophysiology : Official Journal of the International Federation of Clinical Neurophysiology·Yves DauvilliersJacques Montplaisir
Aug 9, 1990·The New England Journal of Medicine·M S Aldrich
Apr 1, 1989·Proceedings of the National Academy of Sciences of the United States of America·S NishinoO Hayaishi
Dec 1, 1995·The International Journal of Neuroscience·R Sandyk
Dec 8, 2006·Expert Opinion on Therapeutic Targets·Seiji Nishino, Nobuhiro Fujiki
Nov 1, 2007·Expert Opinion on Investigational Drugs·Seiji Nishino
Feb 20, 2008·Sleep Medicine Reviews·Giuseppe PlazziRaffaele Ferri
Feb 22, 2007·Sleep·W T LongstrethGerald van Belle
Mar 1, 1982·Experimental Neurology·T L BakerW C Dement
Apr 29, 1998·Clinics in Chest Medicine·K L Choo, C Guilleminault
Sep 3, 2013·Current Biology : CB·Christian R Burgess, John H Peever
Dec 13, 2019·Sleep·Carrie E MahoneyThomas E Scammell
Jan 27, 1987·Brain Research·S S BowersoxR D Ciaranello
Jul 1, 1982·Annals of Neurology·C ThompsonJ D Parkes
May 6, 1983·Science·I N MeffordW C Dement

❮ Previous
Next ❯

Related Concepts

Related Feeds

Adrenergic Receptors: Trafficking

Adrenergic receptor trafficking is an active physiological process where adrenergic receptors are relocated from one region of the cell to another or from one type of cell to another. Discover the latest research on adrenergic receptor trafficking here.